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Abstract 
Antisense oligonucleotides (ASOs) have potential as anti-cancer agents by specifically mod-
ulating genes involved in tumorigenesis. However, little is known about ASO biodistribution 
and tissue pharmacokinetics (PKs) in humans, including whether sufficient delivery to target 
tumor tissue may be achieved. In this preliminary study in human subjects, we used combined 
positron emission and computed tomography (PET-CT) imaging and subsequent modeling 
analysis of acquired dynamic data, to examine the in vivo biodistribution and PK properties of 
LY2181308 - a second generation ASO which targets the apoptosis inhibitor protein survivin. 
Following  radiolabeling  of  LY2181308  with  methylated  carbon-11  ([
11C]methylated- 
LY2181308), micro-doses (<1mg) were administered to three patients with solid tumors 
enrolled in a phase I trial. Moderate uptake of [
11C]methylated-LY2181308 was observed in 
tumors (mean=32.5ng*h /mL, per mg administered intravenously). Highest uptake was seen in 
kidney and liver and lowest uptake was seen in lung and muscle. One patient underwent 
repeat analysis on day 15 of multiple dose therapy, during administration of LY2181308 
(750mg),  when  altered  tissue  PKs  and  a  favorable  change  in  biodistribution  was  seen. 
[
11C]methylated-LY2181308 exposure increased in tumor, lung and muscle, whereas renal 
and hepatic exposure decreased. This suggests that biological barriers to ASO tumor uptake 
seen at micro-doses were overcome by therapeutic dosing. In addition, 
18F-labeled fluoro-
deoxyglucose (FDG) scans carried out in the same patient before and after treatment showed 
up to 40% decreased tumor metabolism. For the development of anti-cancer ASOs, the 
results provide evidence of LY2181308 tumor tissue delivery and add valuable in vivo phar-
macological information. For the development of novel therapeutic agents in general, the 
study exemplifies the merits of applying PET imaging methodology early in clinical investiga-
tions. 
Key words: Positron emission tomography (PET) imaging; antisense oligonucleotide (ASO); cancer 
patients; biodistribution; pharmacokinetic (PK) modeling. 
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Introduction 
Positron Emission Tomography (PET) offers the 
ability to integrate imaging with the investigation of 
novel therapeutics in vivo, making it a powerful tool 
for  translational  experimental  medicine  and  drug 
development.  Following  radiolabeling,  a  compound 
of interest may be visualized, measured and tracked 
to investigate its pharmacological properties in a pa-
tients’  body.  PET  in  combination  with  Computed 
Tomography (PET-CT) allows this to be carried out 
with high specificity and sensitivity. Subsequent use 
of modeling techniques to analyze the dynamic PET 
imaging  data  enables  significant  pharmacokinetic 
(PK) information on the labeled agent to be derived in 
tissues of interest. This methodology can have con-
siderable  advantages  compared  with  conventional 
blood  PK  information:  compound  biodistribution 
may  be  investigated  in  all  tissues  using  only  tracer 
amounts, without the need for invasive biopsies; and 
meaningful  information  may  be  gained  without 
studying  large  patient  groups.  Using  other  radio-
labeled tracers, PET studies may also be used to de-
rive  valuable  pharmacodynamic  (PD)  tissue  func-
tionality information to provide evidence of intended 
drug  activity.  For  example,  15O-labeled  water  PET 
scans or  18F labeled fluorodeoxyglucose (FDG) scans 
may be used before and after experimental treatment 
in the investigation of novel anti-cancer agents to as-
sess  change  in  tumor  perfusion  or  metabolism,  re-
spectively [1, 2]. Thus, PET analysis early in clinical 
testing can provide in vivo proof-of-concept evidence 
and  may  be  particularly  beneficial  if  a  compound’s 
pharmacological properties are not well understood, 
as is the case with antisense oligonucleotides (ASOs) 
[3].  
In  the  past  20  years,  ASO  technology  has 
advanced  from  a  laboratory  tool  to  a  medicinal 
chemistry  platform  [4,  5].  As  potential  therapeutic 
agents,  the  intended  activity  of  ASOs  relies  on 
binding  specific  mRNA  to  inhibit  gene  expression 
associated  with  pathological  disease,  such  as 
tumorigenesis.  Clinical  experiences  with  first 
generation anti-tumor ASOs were discouraging [6, 7], 
which  contributed  to  the  development  of  the  more 
promising second generation ASO molecules. These 
are  characterized  by  chemical  modification  of  their 
ribose  sugar  and  phosphodiester  backbone. 
Pre-clinical studies showed reduced rates of nuclease 
degradation, improved plasma binding protein affin-
ity and rapid tissue biodistribution as a result of the 
modifications, conferring superior biological potency 
and stability. Longer half-lives, increased metabolite 
clearance  and  improved  toxicity  profile  have  also 
been demonstrated [8-14]. Following study of second 
generation ASO plasma PKs in other species, clinical 
phase investigations of second generation ASOs are 
now well underway in oncology. However, the ther-
apeutic potential of ASOs remains dependent on their 
successful target cell delivery in vivo without causing 
dose limiting toxicity due to accumulation in the liver 
or  kidney,  yet  their  tissue  distribution  and  PK/PD 
properties  in  humans  are  not  well  characterized. In 
vivo imaging using PET offers the ability to investigate 
these  important  aspects  of  ASOs  and accelerate  the 
drug discovery process [15, 16].  
LY2181308  is  a  18-mer  2’-O-methoxyethyl- 
(MOE) modified second generation ASO which was 
developed to specifically inhibit survivin. Survivin is 
a member of the inhibitor of apoptosis protein (IAP) 
family that is expressed in many types of cancer [17, 
18].  High  tumor  levels  are  associated  with  worse 
prognosis, but there is a relative lack of expression in 
normal tissues, making it an attractive cancer thera-
peutic target for molecular inhibition [19]. Encourag-
ing  pre-clinical  models  have  led  to  recent 
First-in-Human Dose/Phase I trials of LY2181308 [20, 
21].  Further,  a  carbon-11  [11C]  positron  emitting  la-
beling  method  which  does  not  require  structural 
modification of the ASO has recently been developed 
and tested in baboon PET studies [22]. Building upon 
these studies, we sought to investigate the in vivo bi-
odistribution  of  labeled  LY2181308  in  tumor  and 
normal tissues of cancer patients using PET-CT im-
aging methodologies. Modeling analysis of acquired 
PET  data  was  subsequently  carried  out  to  further 
measure  and  understand  LY2181308  biodistribution 
and  tissue  PKs,  including  during  LY2181308  treat-
ment.  
 
Methods  
This study is a companion to the First-in-Human 
Dose (FHD) study of LY2181308, in which the 750 mg 
dose  was  determined  to  safely  reduce  survivin  in 
tumor tissue [20]. The primary objectives were to in-
vestigate  the  biodistribution  and  pharmacokinetic 
(PK)  properties  of  LY2181308  in  normal  and  tumor 
tissue of cancer patients.  
An external auditing company (Certus, Massa-
chusetts, USA) was employed to assure full regula-
tory  compliance.  Prior  to  administration  of  radio-
labeled LY2181308 to humans, an Administration of 
Radioactive  Substances  Advisory  Committee 
(ARSAC) license was obtained, supported by relevant 
information  derived  from  non-human  primate  do-Theranostics 2011, 1 
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simetry  studies  [22].  Radiolabeled  LY2181308  was 
produced and validated to UK Good Manufacturing 
Practice (GMP) level and  in accordance with Medi-
cines and Health Regulatory Agency (MHRA) regu-
lations. The clinical PET study was carried out with 
conformance to Good Clinical Practice (GCP) princi-
ples  and  full  MHRA  and  ethical  approval  (London 
Multi-Centre  Research  Ethics  Committee 
04/MRE02/52).  All  patients  gave  written  informed 
consent.  
[11C]methylated-LY2181308  was  synthesized  as 
previously described by Dence et al [22]. This has the 
key advantage of not requiring any structural modi-
fication of the ASO for the introduction of the positron 
emitting label. The carbon-11 radioactivity was first 
produced  as  [11C]carbon  dioxide  using  a  GE  PET 
tracer cyclotron. This was subsequently converted to 
[11C]methane  via  a  catalytic  hydrogenation  reaction 
and then to [11C]methyl iodide by a thermal reaction 
with  iodine  in  a  GE  PET  Tracer  MiI  Microlab.  The 
[11C]methyl  iodide  was  then  used  to  randomly 
[11C]methylate  the  oligonucleotide  substrate  under 
neutral  conditions  in  a  GE  Tracerlab  FX-FE  radio-
chemistry  system.  Briefly,  [11C]methyl  iodide 
(<30nmol) was delivered under a flow of helium and 
trapped in a reaction vessel containing (in order  of 
addition) 1.4 mg (0.2μmol) LY2181308 (Eli Lilly and 
Co., Indianapolis, USA), 20 L of 20 mmol phosphate 
buffer solution (pH 7.4), 30 L of ethanol and 250 L 
N,N-dimethylformamide.  The  reaction  vessel  was 
sealed and the reaction mixture heated at 80°C for 3 
min with stirring then cooled to 30C. Heating and 
cooling was repeated a further 2 times before 1.8 mL 
phosphate buffered saline (PBS) was added. The ratio 
of [11C]methyl iodide to LY2181308 set in the labeling 
reaction,  confers  the  high  probability  of  LY2181308 
uni-labeling [22]. The solution resulting from the la-
beling  reaction  was  purified  by  size  exclusion 
high-performance liquid chromatography (SE-HPLC) 
using  a  Superdex  Peptide  Gel  Filtration  Column 
(HR10/300GL, GE Healthcare, UK) and eluted with 
PBS at a flow rate of 1 mL/min. The eluent was mon-
itored  continuously  for  both  radioactivity  and  ab-
sorbance at 254 nm and the fraction eluting between 
11  and  14  min  (the  retention  time  of  reference 
LY2181308) was collected in 9mL PBS to recover the 
final  product.  This  was  then  purified  by  passing  it 
through a sterile low protein binding 0.2  m mem-
brane filter into a sterile vial. The total radiosynthesis 
time was 40-45 min, giving 0.9-1.5 GBq of formulated 
product. Quality control was performed by analyzing 
a 50 uL sample of the formulated product by HPLC. A 
Polymer Labs PLRPS 100 A, 5 um, 150 x 4.6 mm HPLC 
column was used with elution at 1.0 mL/min using 
200  mM  TEAA:acetonitrile  (50:50).  
[11C]methylated-LY2181308  co-eluted  with  reference 
LY2181308, with a retention time of 11 min 5s. 
All three recruited patients underwent a baseline 
dynamic [11C]methylated-LY2181308 PET-CT scan for 
90 minutes after microdose  (<1 mg and <600 MBq) 
intravenous  administration  of 
[11C]methylated-LY2181308  tracer.  A  Biograph-6  Hi 
Rez PET-CT scanner (Siemens Medical Solutions Inc. 
USA) was used for all PET data acquisition and image 
reconstruction procedures. During the scan, nine ve-
nous blood samples were withdrawn at 2, 5, 10, 15, 20, 
30,  45,  60  and  90  minutes  following 
[11C]methylated-LY2181308 injection for conventional 
blood radioactivity assays. Whole blood and plasma 
samples  were  immediately  analyzed  using  a  cali-
brated sodium iodide well counter to determine ra-
dioactivity concentrations. To calculate partitioning of 
[11C]methylated LY2181308 into plasma and red blood 
cells, hematocrit measurements were obtained using a 
CCX  blood  gas  analyzer  (Nova  Biomedical  Corp. 
USA). Of the three patients who entered the study, 
one patient (patient 3) subsequently received multiple 
doses of 750 mg LY2181308 (Eli Lilly and Co., Indi-
anapolis, USA) as 3-hr infusions on days 1, 2, 3, 8, 15, 
and  22.  A  second  [11C]methylated-LY2181308 
PET-CT scan  was  carried  out  on  day  15,  with  the 
[11C]methylated-LY2181308  injection  administered 
half-way  through  the  3  hr  infusion  of  750  mg 
LY2181308.  Patient  3  also  underwent  [18F]FDG 
PET-CT  scans  at  baseline  and  on  day  22  following 
administration of [18F]FDG (≤400MBq) to assess tumor 
metabolism before and after ASO treatment. 
PET  image  data  were  reconstructed  using  an 
ordered  subset  expectation  maximization  (OSEM) 
algorithm for anatomical information and visualiza-
tion  [23]  and  discrete  inverse  Fourier  transform 
(DIFT) reconstruction (similar to filtered back projec-
tion)  for  dynamic  quantification  of  tissue 
time-concentration curves. Frame durations of 9x10s, 
3x30s, 4x60s, 4x120s, 3x300s, and 6x600s were used for 
the dynamic reconstruction. Regions of interest (ROIs) 
were delineated on the PET-CT images for the aorta, 
liver, kidney, muscle, spleen, tumor lesions and ver-
tebral  body  (as  an  indicator  of  marrow  uptake). 
Time-concentration curves for each tissue ROI were 
generated  from  the  mean  concentration  within  the 
ROI for each DIFT reconstruction frame. The integral 
area under the curve during the 90 minutes of data 
acquisition  (AUC0-90:  ng*h/mL)  was  calculated  as  a 
comparative  measure  of  tissue  ROI  exposure  to 
[11C]methylated-LY2181308.  Data  was  corrected  for 
radioactive decay and normalized to an equivalent 1 
mg  [11C]methylated-LY2181308  dose.  Plasma  and Theranostics 2011, 1 
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tissue radioactivity data were interpreted throughout 
as being from the parent compound only: metabolites 
were confidently considered negligible in the 90 min 
post administration time-frame of the study. This is 
because second generation ASOs have been shown to 
have  long  tissue  half-lives  (>7  days)  with  no 
significant build up of metabolites due to their rapid 
clearance [9, 14, 24].  
Kinetic modeling analysis was carried out using 
the dynamic blood and tissue ROI radioactivity data 
recorded, with the blood input function derived from 
the aortic PET-CT ROI imaging data. Both the high 
spatial  resolution  of  the  PET  scanner,  and  the 
advantage of not requiring correction for delay and 
dispersion  (as  with  withdrawn  arterial  blood  data), 
are expected to benefit their accuracy. Indeed, com-
parison  of  image  derived  aortic  concentrations  and 
independently derived venous concentrations in pa-
tients  showed  good  agreement  (Table  2),  indicating 
adequate signal-to-noise ratio and negligible degrad-
ing effects such as partial volume. However, for pa-
tient 2, reliable aortic blood vessel regions could not 
be adequately delineated on the pelvic PET-CT scan 
and so modeling analysis was not carried out on data 
from  this  patient.  Two  models  were  subsequently 
fitted to the PET derived data. The first was an irre-
versible  two-tissue  compartmental  model  with  a 
blood volume term [25]. This model is relatively rigid 
and dependent on a number of assumptions regard-
ing radiotracer partitioning. The transfer of the radio-
tracer  between  compartments  is  described  by  rate 
constants, K1 – the rate of uptake of radiotracer from 
blood into tissue, k2 - the rate of efflux of radiotracer 
from tissue into blood and k3 - the rate of irreversible 
binding within tissues. K1/k2 is the distribution vol-
ume, and represents the ratio of free and reversibly 
bound radiotracer in tissue to blood at equilibrium. 
The second model used was a more general spectral 
analysis  model  with  a  term  for  blood  volume  [26]. 
This is more flexible as it is not restricted to prede-
fined  ‘compartments’  and  requires  few  a  priori  as-
sumptions about the distribution of the radiotracer. It 
is based on identifying a spectrum of kinetic compo-
nents within a given data set which are involved in 
the  regional  uptake  and  portioning  of  radiotracer 
from blood to tissue, allowing for the distinction be-
tween  transient  components  associated  with  radio-
tracer  in  the  tissue  vasculature,  and  reversible  and 
irreversible  components  comprising  the  tissue  re-
sponse to the administered radiotracer. The parame-
ter Ki was estimated from this model using the value 
of the impulse response function at 90 minutes, which 
represents  the  rate  of  irreversible  uptake  of  radio-
tracer from blood. All models were implemented us-
ing Matlab® r2008a (The MathworksTM Inc., Massa-
chusetts, USA).  
Results 
Two female (71 and 66 years) and one male (78 
years)  patient,  who  had  exhausted  all  standard 
anti-cancer therapies, were enrolled between June and 
November 2008. All patients had solid tumors: patient 
1  had  pancreatic  carcinoma,  patient  2  had  colon 
cancer, and patient 3 had mesothelioma. All PET-CT 
scanning  and  treatment  procedures  were  well 
tolerated by patients.  
PET  imaging  data  showed  highest  levels  of 
[11C]methylated-LY2181308 in the renal cortex, liver, 
and spleen: lowest levels were seen in lung and mus-
cle  (Table  1  and  Fig.  1b-e).  Moderate  levels  of 
[11C]methylated-LY2181308  were  observed  in  tumor 
tissue. At baseline, tumor [11C]methylated-LY2181308 
exposure  (AUC0-90),  normalized  to  1mg  intravenous 
administration, ranged between 20.8 to 79.2 ng*h/mL 
(Table 1). Mean tumor exposure was 32.5 ng*h/mL. 
Biliary elimination of [11C]methylated-LY2181308 was 
observed in PET-CT scans, with relatively high radi-
oactivity signals in the gall bladder and bile duct (Fig 
1c-d),  which  was  more  clearly  seen  when  adjacent 
liver uptake was lower in patient 3 on day 15 (Fig 1d). 
High  exposure  of  gall  bladder  and  bile  duct  was 
measured  from  tissue-concentration  curves.  Bowel 
adjacent to the opening of the biliary duct on the right 
side  showed  high  exposure  values,  relative  to  that 
measured in the bowel on the left side of the abdomen 
(Table  1).  Renal  elimination  was  also  visible,  with 
lower  concentrations  of  [11C]methylated-LY2181308 
detected  in  the  renal  pelvis,  ureter  and  bladder, 
compared with the renal cortex (Table 1 and Fig 1e). A 
repeat PET scan on day 15 during LY2181308 therapy 
in  patient  3  showed  a  marked  decrease  of 
[11C]methylated-LY2181308  signal  in  high 
baseline-uptake  organs  (kidney,  liver  and  spleen: 
Figs. 2b-c and Table 1). Conversely, tissue exposure 
increased in tumor tissue and in low baseline-uptake 
organs (Fig 2d and Table 1). No concurrent changes in 
blood time-concentration curves were detected (Fig. 
2a).  
The  blood  time-concentration  curves  derived 
from the PET-CT images (aortic ROI data) were typi-
cal  of  rapid  distribution  into  tissue  (Fig.  2a).  Blood 
concentrations  (AUC0-90  values)  of  [11C]methylated- 
LY2181308 derived from the PET-CT aortic ROI are 
compared with those obtained from discrete venous 
blood samples in Table 2. The values agree well, ver-
ifying the accuracy of the PET-CT image derived aor-
tic  ROI  data  used  as  input  function  for  subsequent 
kinetic  modeling.  Additional  analysis  of  discrete Theranostics 2011, 1 
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blood  samples  withdrawn  during  scanning  showed 
plasma  radioactivity  concentrations  were  1.5  times 
higher than whole blood, with corresponding hema-
tocrit values of 35% (patient 2) and 32% (patient 3), 
demonstrating  [11C]methylated-LY2181308  was  al-
most  entirely  partitioned  into  plasma  rather  than 
other blood components. 
Kinetic  models  used  to  interpret  the  dynamic 
[11C]methylated-LY2181308  PET-CT  image  data  ac-
curately  fitted  the  time-concentration  data  for  most 
tissues (Figs. 2b-d), with the only exceptions regions 
of biliary or renal elimination. Both models fitted well 
and  showed  similar  patterns  of  derived  parameters 
for the tissues analysed (Table 3). Modeling showed 
highest baseline irreversible uptake rates (Ki) in the 
kidney and liver, with moderate Ki values determined 
for spleen and bone marrow of vertebrae (Table 3). 
During  LY2181308  therapy  on  day  15  (patient  3),  a 
marked decrease in the rate of irreversible uptake (Ki) 
and  rate  of  irreversible  tissue  binding  (k3)  was  ob-
served  in  the  liver,  spleen  and  kidney.  No  corre-
sponding large changes in K1/k2 were observed (Table 
3). In muscle and lung, modeling confirmed low base-
line tissue exposure in these tissues (Fig 2d), with very 
low distribution volume (K1/k2) values (Table 3). In 
these organs, most of the radioactivity concentration 
measured  in  the  ROI  may  be  attributed  to 
[11C]methylated-LY2181308  within  the  blood,  as 
quantified by the blood volume terms of the kinetic 
models. This reflects very low tissue extraction during 
transit  of  [11C]methylated-LY2181308  through  the 
capillary bed. During LY2181308 therapy on day 15 
(patient 3), the distribution volumes (K1/k2) in muscle 
and lung substantially increased to measurable val-
ues. A decrease in irreversible binding (k3) was also 
observed (Table 3). These changes most likely reflect a 
combination  of  increased  extraction  but  also  de-
creased binding. 
In  tumor  tissue,  kinetic  modeling  confirmed 
moderate exposure at baseline (Fig 3b) and showed 
moderately  low  distribution  volume  (K1/k2)  values 
(Table 3). The latter may be partially attributed to the 
presence of poorly perfused/necrotic areas within the 
sampled  tumor  ROI.  During  LY2181308  therapy  on 
day  15  (patient  3),  modeling  confirmed  increased 
tumor uptake of [11C]methylated-LY2181308 (Figs 3a 
and  b).  Correspondingly,  the  distribution  volume 
(K1/k2) increased, similar to low baseline-uptake tis-
sues, whereas the rate of irreversible binding (k3) de-
creased, as  observed  for  all  other  tissues  (Table  3). 
Concomitantly, [18F]FDG-PET carried out in patient 3 
following LY2181308 therapy showed a reduction of 
up  to  40%  in  tumor  metabolism,  indicating 
proof-of-concept of LY2181308 as an anti-tumor agent 
[20]. 
Table 1. Normal tissue and tumor uptake of [
11C]methylatedLY2181308, normalized to 1 mg bolus administration 
(AUC0-90: ng*h/mL) 
Tissue  Baseline  Day 15 
  Patient 1  Patient 2  Patient 3  Patient 3 
Kidney (left / right)  525.8 / 516.7  NA / 566.1  376.7 / NA  149.4 / NA 
Liver  242.7    340  98.9 
Gall bladder        187.2 
Bile duct  343.7      195.5 
Bowel (near liver or bile outflow)  218.9      151.0 
Spleen  158.9    156.1  83.3 
Bladder    199.4     
Ureter (left / right)  NA / 262.8  116.9 / 135.8     
Vertebra  101.4  50.8  95.0  52.8 
Tumor (see table footnotes)   79.2* 
73.6† 
36.6‡ 
20.8§  57.5†† 
49.7** 
71.4†† 
84.4** 
Bowel (left side)  65.8      89.6 
Ribs  42.5       
Ilium (bone)    35.2     
Spinal cord  25.3  18.9  35  24.7 
Sternum  20.3       
Lung (left / right)      18.1 / 16.9  NAa /23.9 
Muscle  10.3  14.4  12.5  15.6 
*Pancreas. †Metastatic lymph node. ‡Necrotic tumor core. §Colon. ††Mesothothelioma adjacent to liver. **Mesothelioma adjacent to lung. NA – 
data not available. aNormal left lung data was not available for patient 3 on day 15 as there was insufficient tissue for reliable ROI data in the 
field of view of the post-treatment scan. Theranostics 2011, 1 
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Table 2. Comparison of blood [
11C]methylated-LY2181308 AUC0-90 values, determined from PET-CT images and venous 
samples withdrawn during scanning.
Patients  Aortic PET ROI  Blood Samples 
  Blood 
ng*h/mL 
Blood 
ng*h/mL 
Plasma 
ng*h/mL 
1a  95  NA  NA 
2b  NA  94.4  141.4 
3 (Baseline) 
3 (Day15 ) 
118.8 
108.2 
111.7 
98.5 
163.4 
145.0 
NA – data not available. aNo discrete venous samples were taken for patient 1. bReliable arterial blood vessel regions could not be adequately 
delineated on pelvic scan obtained for patient 2. 
 
Table 3. Kinetic model parameters 
Organs  Patient  Compartmental analysis  Spectral analysis 
    K1/k2a  
(mL blood / mL tissue) 
k3 b  
(rate/min ) 
Ki c  
(mL blood /min / mL tissue) 
    Baseline  Day 15   % change  Baseline  Day15   % change f   Baseline  Day 15   % change  
Kidney  Patient 3 
 
Patient 1 
0.98 
 
4.20 
 
0.79 
 
-19.1 
 
0.0591 
 
0.0275 
0.0100 
 
-83.0   0.0435 
 
0.0563 
0.0043   -90.2 
Liver  Patient 3 
 
Patient 1 
 
1.05 
 
1.24 
0.74  -30.1  0.0358 
 
0.0220 
0.0040  -88.8   0.0258 
 
0.0158 
0.0008  -97.1 
Spleen  Patient 3 
 
Patient 1 
 
0.73 
 
1.12 
0.71  -2.43  0.0126 
 
0.009 
0.0015 
 
-87.9  0.0031 
 
0.0035 
0.000028  -99.1 
Vertebra 
(bone mar-
row) 
Patient 3 
 
Patient 1 
 
0.32 
 
0.59 
0.24  -24.7 
 
0.0291 
 
0.0148 
0.0136  -53.3  0.0062 
 
0.0052 
0.0013  -79.4 
Tumor  
(in liver*) 
Patient 3 
 
Patient 1 
 
0.40 
 
0.20 
0.68  +71.1  0.0180 
 
0.0609 
0.0070 
 
-61.1  0.0037 
 
0.0030 
0.0034  -6.91 
Tumor 
 (in lung*) 
Patient 3 
 
Patient 1 
 
0.12 
 
0.29 
 
0.76  +531  0.0401 
 
0.0338 
0.0024  -94.0  0.0023 
 
0.004 
0.0019  -17.9 
Lung  Patient 3 
 
Patient 1 
 
0.03 
 
NA 
0.13  +358  0.0603 
 
NA 
0.0058  -90.4  0.00006 
 
NA 
0.0001  +89.0 
Muscle  Patient 3 
 
Patient 1 
 
0.01 
 
0.01 
0.05  +349  0.0605 
 
0.0605 
0.0361  -40.3  0.0007 
 
0.0005 
0.0006  -3.64 
% change across all organs/tissues for patient 3 
    K1/k2a  k3 b  Ki c 
    %   %   %  
median    34.4  -85.5  -48.6 
range    -30.0 to +531  -40.3 to -94.0  -99.0 to +89.0 
aK1/k2 is the distribution volume (the ratio of free and reversibly bound [11C]methylated LY2181308 in tissue to blood at equilibrium); bk3 is 
the rate of irreversible binding of [11C]methylated LY2181308 within tissues and cKi is the rate of irreversible uptake of [11C]methylated 
LY2181308 from blood. *Tumors located in liver and lung refers to metastases from primary tumors. NA – data not available. 
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Figure 1. Biodistribution of radiolabeled [
11C]methylated-LY2181308. The molecular structure depicts LY2181308 labeled 
at the N3 position of the thymine residue (panel a); note that [
11C]methylation at the N1 position of the guanine residue may 
also be possible. Representative transverse and coronal AUC30-90 images of [
11C]methylated-LY2181308 uptake (scaled 
between  0  and  555  ng*h/mL)  in  patient  1  prior  to  LY2181308  therapy  (panel  b).  Coronal  AUC30-90  images  of 
[
11C]methylated-LY2181308 uptake (scaled between 0 and 278 ng*h/mL) in patient 3 during day 15 LY2181308 infusion 
(panel c). Both images show relatively high signal in the biliary tree (white arrows), but this is more clearly seen in the image 
from patient 3 following the reduced uptake in the adjacent liver on day 15 (panel c). Time-concentration curves for ROIs in 
patient 1 (panel d-e). 
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Figure 2. Changes in [
11C]methylated-LY2181308 time-concentration curves (ng/mL) with therapeutic LY2181308 dosing 
(750mg) in patient 3. Symbols show observed data. Lines show model fits using the spectral analysis model. Open symbols 
and  black  lines  show  baseline  microdose  [
11C]methylated-LY2181308  data.  Solid  symbols  and  red  lines  show 
[
11C]methylated-LY2181308 data during LY2181308 therapy on day 15. There is no change in concentration in blood (panel 
a). High and medium baseline uptake tissues (liver, kidney, vertebra and spleen) show similar early concentrations, but 
marked decreased concentrations by 90 minutes (panel b and c). Low-baseline uptake tissues of muscle and lung show 
increased [
11C]methylated-LY2181308 concentrations (panel d). 
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Figure 3. Changes in tumor [
11C]methylated-LY2181308 uptake with LY2181308 therapy in patient 3 (scaled between 0 
and 110 ng*h/mL). Panel a: Images of AUC30- 90 of [
11C]methylated-LY2181308 prior to therapy (top row) and with day 15 
infusion (bottom row), showing increased concentrations within mesothelial tumor adjacent to the lung (left column) and 
liver (right column). Panel b: Time-concentration curves from ROIs delineated on the mesothelial tumor adjacent to lung 
and adjacent to the liver (shown in green on panel a). Symbols show observed data. Lines show model fits using the spectral 
analysis model. Open symbols and black lines show baseline microdose [
11C]methylated-LY2181308 data. Solid symbols and 
red lines show [
11C]methylated-LY2181308 data with 750 mg infusion of LY2181308 on day 15. 
 
Discussion  
This  study  contains  novel  imaging  data  which 
describes for the first time biodistribution of a second 
generation MOE modified ASO LY2181308 in cancer 
patients. This was made possible by radiolabeling the 
ASO  molecule  with  carbon-11  [22],  allowing  PET 
studies in human subjects during a Phase I trial. The 
adherence  to  quality  standards  throughout  allowed 
consistent  and  accurate  measurement  of  the 
distribution of [11C]methylated-LY2181308. This was 
observed to distribute rapidly into tissue, despite its 
size of 6778 Da [27], which enabled precise evaluation 
of tissue kinetics within the short 20-min half-life of Theranostics 2011, 1 
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carbon-11. The baseline PET data was collected fol-
lowing  microdose  infusion  of 
[11C]methylated-LY2181308  in  three  patients.  This 
experimental  approach  is  on  a  similar  scale  to 
pre-clinical in-vivo animal biodistribution assessments 
[22] and has the advantage of only requiring tracer 
amounts  of  compound.  The  results  yielded  unique 
and  valuable  human  biodistribution  and  tissue  PK 
information of labeled LY2181308 early in its clinical 
development.  In  addition,  analysis  during  multiple, 
pharmacologically relevant doses of LY2181308 in one 
patient showed substantial and favorable changes in 
the  biodistribution  of  [11C]methylated  LY2181308. 
This suggests that biological barriers to tumor ASO 
uptake may be overcome, and normal tissue toxicity 
minimised, by ASO dosing levels/schedules.  
Overall, the biodistribution information and PK 
data obtained is generally consistent with pre-clinical 
assessments of second generation ASOs, which have 
shown remarkably similar properties across different 
species [9, 14]. Importantly, moderate yet comparable 
uptake  of  [11C]methylated-LY2181308  was  seen  in 
tumor tissue in all three patients showing successful 
ASO  tumor  penetration.  This  is  consistent  with  the 
detection of unlabeled LY2181308 in tumor tissue by 
immunohistochemistry  [28]  and  predictive  models 
[29].  As  expected  from  other  preclinical  studies  of 
unlabeled  second  generation  ASOs  with  phos-
phodiester  backbone  and  MOE  modification, 
[11C]methylated-LY2181308  exposure  was  highest  in 
the kidney followed by liver, spleen, and bone mar-
row of vertebrae [30]. The results also agree with prior 
biodistribution  and  tumor  uptake  studies  of 
[11C]methylated LY2181308 in rodents [22].  
Image  derived  arterial  blood  concentrations  of 
[11C]methylated  LY2181308  were  comparable  with 
blood concentrations conventionally determined from 
discrete  venous  blood  samples  (Table  2).  This 
indicates  robust  image  arterial  blood  concentration 
data, which was subsequently used as the blood input 
function in PET kinetic modeling analysis. For most 
organs,  both  the  analytical  models  used  here  de-
scribed the PET data well, with slightly better fits with 
the  spectral  analysis  model.  Neither  models  fitted 
well in regions of biliary or renal elimination. This is 
because both models are based on radioactivity being 
delivered to tissues via the arterial blood, and do not 
model activity being transferred within bile and urine.  
A key limitation of the study is that the biodis-
tribution  and  PK  properties  of 
[11C]methylated-LY2181308  could  not  be  directly 
compared to unlabeled LY2181308. It is possible that 
labeling the molecule could affect its  stability, solu-
bility and ‘cellular penetration’ properties. However, 
one of the key advantages of the 11C labeling method 
is  that  no  structural  modification  of  the  ASO  is  re-
quired to introduce the positron emitting precursor - 
the sugar and phosphodiester backbone already offers 
a handle for the introduction of the carbon-11 label. 
The  labeled  and  unlabeled  molecules  also  elute  to-
gether when purified with high performance gel fil-
tration, demonstrating close molecular size and simi-
lar  solubility.  In  general,  MOE  modified  ASOs  also 
show very similar biodistribution and PK properties 
across various animal species, despite molecular dif-
ferences [9, 14, 30]. Our PET-CT biodistribution stud-
ies of labeled LY2181308 in humans, and those carried 
out using PET in baboons [22], are also very similar. In 
addition,  both  image  derived  blood  concentrations 
and  venous  blood  derived  blood  concentrations 
(Table 2) agreed with the predicted plasma concen-
tration for the 750 mg dose of unlabeled LY2181308 
from  pre-clinical  modeling  [24]  and  conventional 
plasma  PK  analysis  of  unlabeled  LY2181308  from 
phase 1 studies [20, 21].  Further, second generation 
ASO molecules are known to be very stable in vivo, 
with  half-lives  longer  than  7  days  (1-4  weeks  de-
pending  on  chemistry  and  sequence).  Very  little 
breakdown  product  is  detected  in  tissue  compared 
with  parent  compound,  and  even  using  sensitive 
techniques, metabolites of MOE modified ASOs are 
not detected in plasma or tissue within several hours 
post-dose administration [9, 14]. Thus, it appears that 
there are no major size stability or functional differ-
ences in the labeled ASO molecule when compared 
with prior studies of unlabeled LY2181308 and other 
similar unlabeled ASO molecules. However, a change 
in ‘cellular penetration properties’ due to the intro-
duction of the 11C label cannot be ruled out. It would 
therefore  be  beneficial  to  investigate  this  in  future 
studies, and the potential differences between unla-
beled and labeled molecules should be borne in mind 
in the interpretation of results.  
Several factors may affect tissue uptake of ASOs 
from blood plasma, including blood flow/perfusion, 
plasma  concentration,  and  binding  affinity  gradient 
between plasma and tissue. Second generation phos-
phorothioate  backbone  ASOs  are  known  to  bind  to 
plasma proteins, largely as a function of non-specific 
low-affinity  binding  to  hydrophilic  sites.  This  pre-
vents rapid loss of ASOs through urinary excretion 
and promotes systemic uptake, but many biological 
barriers  may  subsequently  impede  penetration  of 
ASOs from plasma proteins into target cells [4, 9, 14, 
31]. While the PET data from the ROI analyzed does 
not  provide  information  on  what  determines 
LY2181308 tissue uptake, retention or subcellular dis-
tribution, our results support prior evidence that in-Theranostics 2011, 1 
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dicates  ASO  tissue  biodistribution  is  primarily  de-
pendent  on  the  differential  expression,  availability 
and avidity of cell surface binding sites that promote 
ASO uptake [4, 9]. For example, receptors present on 
phagocytically  active  cells  of  the  reticuloendothelial 
system, such as active histiocytes, and von Kuppfer 
macrophages,  are  known  to  predispose  liver  and 
spleen to high ASO uptake [4, 9, 32-34].  
Although  only  performed  in  one  patient,  clear 
changes in tissue distribution and kinetics were ob-
served  during  therapeutic  dosing  of  750  mg 
LY2181308,  despite  negligible  changes  in 
[11C]methylated-LY2181308 blood concentration. The 
changes were therapeutically advantageous, as tumor 
uptake  increased  whereas  kidney,  liver  and  spleen 
uptake  reduced.  This  provides  additional  data 
describing non-linear ASO tissue distribution kinetics 
[9]. It also indicates that dosing levels/schedules may 
overcome biological barriers to ASO target tissue de-
livery, and enable minimization of toxicity in normal 
organs,  thereby  supporting  the  concept  of  repeated 
infusions of 750 mg LY2181308. Previous studies have 
shown that redistribution of ASO at the cellular and 
subcellular level may lead to changes in the uptake 
pattern  over  time  [35,  36].  However,  our  modeling 
analysis  results  suggest  saturation  or 
down-regulation  of  high-affinity  tissue/plasma 
binding  sites  are  most  likely  to  account  for  the  ob-
served  changes  in  biodistribution  following  higher 
drug  concentrations/multiple  administrations.  For 
example,  saturation  or  down-regulation  of 
high-affinity plasma binding sites could result in an 
increase  of  either  unbound  ASO,  or  ASO  which  is 
bound to lower affinity plasma proteins such as al-
bumin  [37].  In  turn,  this  could  change  the  affinity 
gradient  between  plasma  and  tissue,  thereby  pro-
moting ASO delivery to tissues via lower affinity re-
ceptor-mediated endocytosis, or enhanced pinocyto-
sis or endothelial permeation. At the same time, sat-
uration  or  down-regulation  of  high-affinity  tissue 
binding sites would result in decreased high-affinity 
ASO-protein  binding  transit.  Both  these  proposed 
mechanisms are consistent with the observed reduced 
retention (k3) of all tissues during LY2181308 therapy. 
The former plasma saturation mechanism appeared to 
have  the  greater  effect  upon  tissues  with  negligible 
baseline extraction, such as muscle and lung, whereas 
the  latter  tissue  saturation  mechanism  appeared  to 
have the greater effect upon tissues with high baseline 
uptake, such as the kidney, liver and spleen. Notably, 
similar changes to high baseline uptake organs have 
been  observed  in  rodents,  where  uptake  of 
[11C]methylated-LY2181308  was  partially  blocked  in 
the  presence  of  higher  amounts  of  unlabeled  ASO 
[22].  For  tumor  tissue,  the  plasma  binding  protein 
saturation  mechanism  is  proposed  as  the  major  in-
fluence  to  account  for  increased  uptake  of 
[11C]methylated-LY2181308  during  therapy.  But  the 
increases in extraction are potentially more complex 
in tumor. This is due to the physiological changes that 
may  occur  in  tumor  following  tumor  cell  arrest, 
apoptosis or necrosis as a result of LY2181308 treat-
ment, as supported by the partial metabolic responses 
measured with FDG-PET. For example, reduction in 
tumor  pressure  or  an  increase  in  perfusion  volume 
could  independently  increase  distribution  volume 
(K1/k2) with unpredictable changes in the rate of tu-
mor uptake (K1).  
In summary, the data obtained here adds to the 
knowledge of ASO biodistribution and tissue PKs. It 
shows  successful  ASO  tumor  penetration,  but  indi-
cates that target tissue uptake may be confined by the 
affinity  gradient  between  plasma  and  tumor  tissue 
and/or  the  processes  of  endothelial  permeation  or 
endocytosis.  Although  not  definitive  as  the  data  is 
limited, the observation that ASO biodistribution fa-
vorably changed during therapy suggests that ASO 
dosing levels/schedules may influence the biological 
factors  controlling  tissue  uptake.  The  results  also 
exemplify  how  PET-CT  imaging  and  modeling 
methodology may be applied to enhance the clinical 
development of novel therapeutic compounds.  
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